🏛️ Verified NIH Record • Updated 2026-01-09
IC-8 Apthera IOL New Enrollment Post Approval Study (NCT06060041)
🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Bausch & Lomb Incorporated
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to verify the post-market safety of the IC-8 Apthera IOL after the treatment of posterior capsular opacification (PCO), an expected complication related to IC-8 Apthera IOL implantation.
Who can join: Review the eligibility criteria below.
Location: Trinity Research Group, LLC — Dothan, Alabama
Age range: 22 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (14 Sites)
- Trinity Research Group, LLC — Dothan, Alabama
- Feinerman Vision Center — Newport Beach, California
- Argus Research Center — Cape Coral, Florida
- Stephenson Eye Associates — Venice, Florida
- Virdi Eye Clinic and Laser Vision Center — Rock Island, Illinois
- Price Vision Group — Indianapolis, Indiana
- Grene Vision Group — Wichita, Kansas
- Oakland Eye — Birmingham, Michigan
- Vance Thompson Vision - Omaha — Omaha, Nebraska
- Eye Associates of New Jersey — Dover, New Jersey
- Northern New Jersey Eye Institute — South Orange, New Jersey
- Ophthalmic Partners, PC — Bala-Cynwyd, Pennsylvania
- Berkeley Eye Center — Sugar Land, Texas
- Utah Eye Centers — Bountiful, Utah
📞 Contact the Study Coordinator
Phone: (818) 369-9137
Email: jennifer.laskowski@bausch.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cataract
- Clinical Study of a Fluid Accommodating Intraocular Lens (IOL) Design — San José,
- Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution — Glendale, Arizona
- Impact of a Novel Extended Depth of Focus Intraocular Lens on Visual and Lifestyle Enhancement — Babylon, New York
- A Prospective, Single-Arm Clinical Evaluation of Visual, Refractive, and Patient-Reported Outcomes Following Bilateral Implantation of the TECNIS PureSee™ Extended Depth of Focus Intraocular Lens — Sioux Falls, South Dakota
- Visual Acuity Outcome Differences Between the Alcon Vivity Toric IOL and RxSight LAL+ — Bradenton, Florida
- Visual Outcomes of Tecnis Symfony Opti-Blue EDOF Intraocular Lens (IOL) — Greenwich, Connecticut
Explore by condition: All Cataract clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.